Supplementary Figure 5 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer

Supplementary Figure 5: Effects of concomitant treatments during denosumab treatment Heatmaps summarizing log2 fold changes from statistical analysis of functional markers CD137, CD27, CD40, CD40L, CD71, CD95, CTLA-4, HLA-DR, ICOS, Ki-67, NKG2D, OX40, PD-1, PD-L1, PD-L2, TIGIT and TIM3 when comparing (A) patients that received only chemotherapy or chemotherapy and steroids with patients that did not receive chemotherapy or steroids at pretreatment timepoint 1 (TP1) and post-treatment timepoints 2 and 3 (TP2 and TP3); (B) patients received only steroids with patients that received only chemotherapy or chemotherapy and steroids at TP2 and TP3; (C) patients that received only steroids with patients that did not receive chemotherapy or steroids at TP2 and TP3. Each box in the heatmap represents a lymphocyte cluster that was labeled according to the nearest landmark node they connect to on the scaffold map and ordered by cell count abundance. The pseudocolor represents clusters that showed a significant difference (q<0.05) in the log2 fold change, with red being significantly higher, while blue being significantly lower in group 2 of the two comparison groups.